(RTTNews) – Shares of Mirum Pharmaceuticals, Inc. (MIRM) fell 20% on Tuesday morning. The biopharmaceutical company announced the value of a public offering of 3. 75 million non-unusual shares.
The MIRM is lately at $19. 00, $5. 00 or 20. 83% less, on the Nasdaq.
The Company set a price on the public that offered 3. 75 million non-unusual shares to $20 according to the share, raising approximately $75. 0 million after fees and commissions.
Mirum Pharmaceuticals is a clinically staged biopharmaceutical company on the progression and commercialization of a complex line of new treatments for debilitating liver disease. Mirum’s main candidate product, maralixibat, is an experimental oral drug in progression for Alagille syndrome, progressive family intrahepathic colestase and bile. Atresia.